Complexities of MRD Assays in ALL: A Guide for the Practicing Clinician.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2025-07-12 DOI:10.1159/000547423

Jerry Luo, Lori Muffly

引用次数: 0

Abstract

Assessment of measurable residual disease (MRD) is an important component of acute lymphoblastic leukemia (ALL) management. Quantification of MRD may be performed through a variety of assays, each with differing sensitivity for leukemia detection. In this review article, we focus on complexities that the treating physician may face when considering MRD in ALL. New information on the optimal MRD assay for Philadelphia chromosome positive ALL, specimen source for MRD testing (eg, blood, bone marrow, cerebrospinal fluid), when to test, and updates on MRD in T-cell ALL are included.

查看原文本刊更多论文

ALL中MRD检测的复杂性：临床实践指南。

可测量残留病（MRD）的评估是急性淋巴细胞白血病（ALL）治疗的重要组成部分。MRD的定量可以通过多种检测方法进行，每种检测方法对白血病的敏感性不同。在这篇综述文章中，我们关注治疗医生在考虑ALL的MRD时可能面临的复杂性。包括费城染色体阳性ALL的最佳MRD检测、MRD检测的标本来源（如血液、骨髓、脑脊液）、何时检测以及t细胞ALL MRD的最新信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.